Boston, MA 09/17/2014 (wallstreetpr) – The clinical trial of Lotus™ Valve System of Boston Scientific Corporation (NYSE:BSX) is enduringly proving its performance in terms of being the less persistent treatment for aortic stenosis patients. The company released new data, according to which the performance is demonstrated to be strong for patients who are at high possibility for the treatment involving surgical valve replacement.
Vital Facts of the Data
The clinical trial called REPRISE II has been confirmed as a safe and effective one with over 86% patients showing signs of complete lack of leaking or paravalvular aortic regurgitation. Also none of the patients demonstrated moderate or severe aforesaid condition.
At the 26th Transcatheter Cardiovascular Therapeutics meeting, the data from REPRISE I and REPRISE II studies were presented. While REPRISE I clinical trial has already come out with the results, the latter one is still going on by the way of multi-center and single-arm study. The motive behind undertaking REPRISE II studies is to evaluate the performance as well as safety aspects of Lotus Valve System among patients suffering from rigorous calcific aortic stenosis. These patients are considered as the ones at risk for valve replacement through surgical processes.
In the study, 120 patients were involved at 14 different locations situated at the U.K., France, Germany and Australia.
What Experts Say?
The MonashHeart Director at Melbourne-based Monash Medical Centre, Professor Ian Meredith says that the data from REPRISE II demonstrated sustained and strong clinical benefits. He added that the results explained about bringing down the rate of cardiovascular mortality and paravalvular regurgitation, along with the brilliance in terms of hemodynamics.
The characteristics, as well as advantages of the Lotus Valve System, have been cemented by way of positive clinical data. The system shall now be able to offer ability of achieving primary valve placement with precision because of being loaded with the latest technology.
